RNS Number : 0186C
MaxCyte, Inc.
16 June 2021
MaxCyte, Inc.
("MaxCyte" or the "Company")
Publication of Annual Report and Accounts
Gaithersburg, Maryland - 16 June 2021: MaxCyte (LSE: MXCT, MXCN), a leading provider of cell-engineering platform technologies for next generation cell-based therapies, today announces that it has published its Annual Report and Accounts for the year ending 31 December 2020.
The Annual Report is available to view on the Company's website at https://investors.maxcyte.com/news-events/documents-presentations and printed copies of the reports have been posted to those shareholders who have elected to continue to receive paper communications.
###
About MaxCyte
MaxCyte is a leading commercial cell-engineering company focused on providing enabling platform technologies to advance innovative cell-based research as well as next-generation cell therapeutic discovery, development and commercialisation. MaxCyte's existing customer base ranges from large biopharmaceutical companies, including all of the top 10, and 20 of the top 25, pharmaceutical companies based on 2020 global revenue, to hundreds of biotechnology companies and academic centres focused on translational research. MaxCyte has granted 13 strategic platform licences to commercial cell therapy developers. Including these strategic platform licences, MaxCyte has granted pre-clinical and clinical licences to academic and industry customers covering over an estimated 140 programmes, of which an estimated 100 programmes are for clinical use. MaxCyte was founded in 1998 and is headquartered in Gaithersburg, Maryland, US. For more information, visit www.maxcyte.com.
For further information please contact:
|
MaxCyte Inc.
Doug Doerfler, Chief Executive Officer
Amanda Murphy, Chief Financial Officer
|
+1 301 944 1660
|
|
Nominated Adviser and Joint Corporate Broker
Panmure Gordon
Emma Earl
Freddy Crossley
Corporate Broking
Rupert Dearden
|
+44 (0)20 7886 2500
|
|
Joint Corporate Broker
Numis Securities Limited
James Black
Duncan Monteith
|
+44 (0)20 7260 1000
|
|
Joint Corporate Broker
Stifel Nicolaus Europe Limited
Healthcare Investment Banking
Nicholas Moore / Ben Maddison / Samira Essebiyea
Corporate Broking
Nick Adams
|
+44 (0) 20 7710 7600
|
|
Financial PR Adviser
Consilium Strategic Communications
Mary-Jane Elliott / Chris Welsh
|
+44 (0)203 709 5700
maxcyte@consilium-comms.com
|
This information is provided by RNS, the news service of the
London Stock Exchange. RNS is approved by the Financial Conduct Authority to act as a Primary Information Provider in the
United Kingdom. Terms and conditions relating to the use and distribution of this information may apply. For further information, please contact
rns@lseg.com or visit
www.rns.com.
RNS may use your IP address to confirm compliance with the terms and conditions, to analyse how you engage with the information contained in this communication, and to share such analysis on an anonymised basis with others as part of our commercial services. For further information about how RNS and the
London Stock Exchange use the personal data you provide us, please see our
Privacy Policy.
END
ACSFFFLLRSIELIL
